AbbVie (ABBV) Stock Forecast & Price Target

$185.16

+2.99 (+1.64%)

(As of 07/26/2024 ET)

AbbVie - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 15 Analyst Ratings

Based on 15 Wall Street analysts who have issued ratings for AbbVie in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 2 have given a hold rating, and 13 have given a buy rating for ABBV.

Consensus Price Target

$188.71
1.92% Upside

High Forecast	$214.00
Average Forecast	$188.71
Low Forecast	$150.00

According to the 15 analysts' twelve-month price targets for AbbVie, the average price target is $188.71. The highest price target for ABBV is $214.00, while the lowest price target for ABBV is $150.00. The average price target represents a forecasted upside of 1.92% from the current price of $185.16.

Type	Current Forecast 7/29/23 to 7/28/24	1 Month Ago 6/29/23 to 6/28/24	3 Months Ago 4/30/23 to 4/29/24	1 Year Ago 7/29/22 to 7/29/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	12 Buy rating(s)	10 Buy rating(s)	7 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)	9 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$188.71	$179.64	$174.31	$163.88
Forecasted Upside	1.92% Upside	13.15% Upside	12.16% Upside	10.26% Upside

Get AbbVie Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

Ad Behind the Markets

J.P. Morgan’s DIRE Warning

When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."

Click here to see why Wall Street is in PANIC mode >>>

ABBV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ABBV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

AbbVie Stock vs. The Competition

Type	AbbVie	Medical Companies	S&P 500
Consensus Rating Score	2.87	2.72	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	1.92% Upside	3,118.44% Upside	9.08% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/26/2024	Cantor Fitzgerald 3 of 5 stars	L. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$200.00 ➝ $200.00	+7.14%
7/26/2024	Wells Fargo & Company 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$200.00 ➝ $205.00	+12.53%
7/26/2024	Truist Financial 1 of 5 stars		Reiterated Rating	Buy ➝ Buy	$195.00 ➝ $210.00	+15.28%
7/26/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$187.00 ➝ $200.00	+9.79%
7/19/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$180.00 ➝ $214.00	+24.50%
7/11/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$191.00 ➝ $196.00	+15.61%
Get the Latest News and Ratings for ABBV and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.
7/3/2024	Piper Sandler Companies Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$190.00 ➝ $190.00	+14.48%
6/5/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$185.00	+14.08%
3/22/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$188.00 ➝ $190.00	+6.41%
2/5/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$181.00 ➝ $189.00	+12.05%
1/29/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Lugo Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
12/11/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$173.00	+15.89%
11/9/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$150.00	+5.60%
10/20/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral	$157.00 ➝ $150.00	+3.08%
7/12/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$170.00 ➝ $160.00	+18.02%
4/5/2023	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
2/22/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Peer Perform
2/10/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral	$157.00 ➝ $154.00	+1.83%
2/10/2023	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform	$135.00 ➝ $153.00	+2.89%
2/10/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Market Perform	$135.00 ➝ $153.00	+2.89%
11/8/2022	Societe Generale Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$155.00 ➝ $140.00	-7.32%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 02:34 AM ET.

ABBV Forecast - Frequently Asked Questions

What is AbbVie's forecast for 2024?: According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for AbbVie is $188.71, with a high forecast of $214.00 and a low forecast of $150.00.
Should I buy or sell AbbVie stock right now?: 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ABBV shares.
Does AbbVie's stock price have much upside?: According to analysts, AbbVie's stock has a predicted upside of 12.30% based on their 12-month stock forecasts.
Has AbbVie been upgraded by Wall Street analysts recently?: Over the previous 90 days, AbbVie's stock had 1 upgrade by analysts.
What analysts cover AbbVie?: AbbVie has been rated by research analysts at Barclays, BMO Capital Markets, Cantor Fitzgerald, HSBC, Morgan Stanley, Piper Sandler, Piper Sandler Companies, Truist Financial, and Wells Fargo & Company in the past 90 days.
Do Wall Street analysts like AbbVie more than its competitors?: Analysts like AbbVie more than other "medical" companies. The consensus rating score for AbbVie is 2.87 while the average consensus rating score for "medical" companies is 2.72. Learn more on how ABBV compares to other companies.